Mast cell activation syndrome as a significant comorbidity in sickle cell disease.
about
Mast Cell Activation SyndromeProtective Effects of Alisma orientale Extract against Hepatic Steatosis via Inhibition of Endoplasmic Reticulum Stress.Inflammatory targets of therapy in sickle cell disease.Mast Cell-Mediated Mechanisms of Nociception.Alteration of lymphocyte phenotype and function in sickle cell anemia: Implications for vaccine responses.
P2860
Mast cell activation syndrome as a significant comorbidity in sickle cell disease.
description
2014 nî lūn-bûn
@nan
2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Mast cell activation syndrome as a significant comorbidity in sickle cell disease.
@ast
Mast cell activation syndrome as a significant comorbidity in sickle cell disease.
@en
Mast cell activation syndrome as a significant comorbidity in sickle cell disease.
@nl
type
label
Mast cell activation syndrome as a significant comorbidity in sickle cell disease.
@ast
Mast cell activation syndrome as a significant comorbidity in sickle cell disease.
@en
Mast cell activation syndrome as a significant comorbidity in sickle cell disease.
@nl
prefLabel
Mast cell activation syndrome as a significant comorbidity in sickle cell disease.
@ast
Mast cell activation syndrome as a significant comorbidity in sickle cell disease.
@en
Mast cell activation syndrome as a significant comorbidity in sickle cell disease.
@nl
P2860
P1476
Mast cell activation syndrome as a significant comorbidity in sickle cell disease.
@en
P2093
Lawrence B Afrin
P2860
P304
P356
10.1097/MAJ.0000000000000325
P407
P577
2014-12-01T00:00:00Z